FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2023/02/049803 [Registered on: 17/02/2023] Trial Registered Prospectively
Last Modified On: 15/02/2023
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   A CLINICAL TRIAL TO STUDY THE EFFECT OF TWO DRUGS, FERRIC-CARBOXY MALTOSE AND IRON SUCROSE COMPLEX FOR TREATMENT OF IRON DEFICIENCY ANEMIA IN PREGNANT WOMEN 
Scientific Title of Study   COMPARISON OF IRON SUCROSE COMPLEX AND FERRIC CARBOXYMALTOSE FOR TREATMENT OF IRON DEFICIENCY ANEMIA IN ANTE-PARTUM PATIENTS: A RANDOMIZED CONTROL TRIAL 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Ankit Kumar Dangi 
Designation  Post MBBS Primary DNB Resident 
Affiliation  Bhagat Phool Singh Govt. Medical College for Women, Khanpur kalan, Sonepat 
Address  F-54 , Bhagat Phool Singh Govt. Medical College for Women, Khanpur kalan, Sonepat, Haryana

Sonipat
HARYANA
131305
India 
Phone  8295857574  
Fax    
Email  drankitkumardangi@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr SUNITA SIWACH 
Designation  PROFESSOR 
Affiliation  Bhagat Phool Singh Govt. Medical College for Women, Khanpur kalan, Sonepat 
Address  Dept of OBS & Gynae , Bhagat Phool Singh Govt. Medical College for Women, Khanpur kalan, Sonepat, Haryana

Sonipat
HARYANA
131305
India 
Phone  9812266400  
Fax    
Email  siwachsunita@ymail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Ankit Kumar Dangi 
Designation  Post MBBS Primary DNB Resident 
Affiliation  Bhagat Phool Singh Govt. Medical College for Women, Khanpur kalan, Sonepat 
Address  F-54 , Bhagat Phool Singh Govt. Medical College for Women, Khanpur kalan, Sonepat, Haryana

Sonipat
HARYANA
131305
India 
Phone  8295857574  
Fax    
Email  drankitkumardangi@gmail.com  
 
Source of Monetary or Material Support  
BPS Govt. Medical College for Women, Khanpur kalan, Sonepat, Haryana 131305 
 
Primary Sponsor  
Name  BPS Govt. Medical College for Women, Khanpur kalan 
Address  BPS Govt. Medical College for Women, Khanpur kalan, Sonepat, Haryana 131305 
Type of Sponsor  Government medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Ankit Kumar Dangi  BPS Govt. Medical College for Women, Khanpur kalan  Ward No:2-Department of Obstetrics and Gynaecology, BPS Govt. Medical College for Women, Khanpur kalan, Sonepat, Haryana 131305
Sonipat
HARYANA 
8295857574

drankitkumardangi@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics Committee BPS Govt. Medical College for Women, Khanpur kalan  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: O990||Anemia complicating pregnancy, childbirth and the puerperium,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  inj,IV,Ferric-carboxymaltose,veuses,inj,IV,Iron,Sucrose,Complex  Ante-partum,patients,having,iron,deficiency,anemia,will,be,randomly,divided,in,two,groups.Total,iron,deficit,will,be,calculated,using,gazoni,formula,and,one,group,will,be,given,inj,IV,Ferric-carboxymaltose-1000mg,per,dose,once,weekly,till,the,total,iron,deficit,is,completed,and,other,group,will,be,given,inj,IV,Iron-Sucrose,Complex-300mg,per,dose,in,200ml,normal,saline,twice,weekly,till,the,total,iron,deficit,is,balanced,and,rise,in,Hb,and,serum,ferritin,will,be,noted,from,baseline,at,interval,of,3,6,and,9,weeks,from,start,of,treatment. 
Intervention  intravenous,iron,prepration  Ante-partum,patients,having,iron,deficiency,anemia,will,be,treated,with,injectable,iron,theraphy,accoding,to,total,iron,deficiency,calculated,based,on,gazoni,formula 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  35.00 Year(s)
Gender  Female 
Details  Ante-partum women
Age between 18 to 35 years.
Hemoglobin between 6-9.9 gm %..
Iron deficiency anemia
24-34 weeks of period of gestation
 
 
ExclusionCriteria 
Details  Other than Iron Deficiency Anemia
Acute or Chronic Liver diseases
HIV
1st Trimester of Pregnancy
Serum transaminases > 1.5 times upper limit of normal
Serum Creatinine > 2.0 mg/dL
History of allergic reaction to intravenous iron infusion
Anemia due to other causes Thalassemia patient
Iron metabolic disorder
Hemosiderosis
Hemochromatosis
Untreated Pyelonephritis
Anaphylactic Reaction
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   On-site computer system 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
Change in Hb level from baseline on follow-up visits  baseline, 3 weeks, 6 weeks, 9 weeks 
 
Secondary Outcome  
Outcome  TimePoints 
Change in RBC indices, RDW, change in serum ferritin levels,change in fatigue levels, safety and side effects of treatment and peri-natal outcome (in terms of time of delivery/ abortion/preterm delivery)  baseline, 3 weeks, 6 weeks, 9 weeks 
 
Target Sample Size   Total Sample Size="220"
Sample Size from India="220" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3/ Phase 4 
Date of First Enrollment (India)   28/02/2023 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="1"
Days="1" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   not yet 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Whether parenteral iron therapy in form on ferric carboxymaltose in terms of efficacy, safety and compliance has advantage over iron sucrose complex for treatment of iron deficiency anemia in ante-partum patients?


Women presenting with iron deficiency anemia and Hb 6-9.9gm % will be randomized based computer generated block randomization technique in group 1 or group 2.

Group1:- will be formed by the patients receiving Ferric Carboxymaltose        

Group 2:- will be formed by the patients receiving iron sucrose complex.

Follow-up visits will be done after 3, 6 and 9 weeks from start of treatment. Primary outcome to note will be change in Hb level from baseline on follow-up visits. Secondary outcomes will be change in RBC indices, RDW, change in serum ferritin levels, change in fatigue levels (LASA to measure improvements in fatigue scores and a 10 point numeric scale to assess the feeling of well-being), safety and side effects of treatment and peri-natal outcome (in terms of time of delivery/ abortion/preterm delivery). 

 
Close